BR112016020381A8 - sistemas e métodos para liberação de drogas para tratamento do câncer de bexiga com gencitabina. - Google Patents
sistemas e métodos para liberação de drogas para tratamento do câncer de bexiga com gencitabina.Info
- Publication number
- BR112016020381A8 BR112016020381A8 BR112016020381A BR112016020381A BR112016020381A8 BR 112016020381 A8 BR112016020381 A8 BR 112016020381A8 BR 112016020381 A BR112016020381 A BR 112016020381A BR 112016020381 A BR112016020381 A BR 112016020381A BR 112016020381 A8 BR112016020381 A8 BR 112016020381A8
- Authority
- BR
- Brazil
- Prior art keywords
- gemcitabine
- methods
- bladder
- bladder cancer
- drug release
- Prior art date
Links
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 title abstract 6
- 229960005277 gemcitabine Drugs 0.000 title abstract 6
- 206010005003 Bladder cancer Diseases 0.000 title abstract 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 201000005112 urinary bladder cancer Diseases 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 210000005068 bladder tissue Anatomy 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Nanotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
dispositivos e métodos de liberação de drogas são fornecidos para administração de gencitabina a um paciente em necessidade de tratamento de câncer da bexiga por administração intravesical de gencitabina na bexiga do paciente para alcançar uma concentração sustentada da gencitabina na urina na bexiga suficiente para produzir uma concentração terapeuticamente eficaz da gencitabina nos tecidos da bexiga. em modalidades, a administração local na bexiga do paciente é a uma quantidade média de 1 mg/dia a cerca de 300 mg/dia da gencitabina (fbe).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461949215P | 2014-03-06 | 2014-03-06 | |
PCT/US2015/019262 WO2015134911A1 (en) | 2014-03-06 | 2015-03-06 | Drug delivery systems and methods for treatment of bladder cancer with gemcitabine |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112016020381A2 BR112016020381A2 (pt) | 2017-08-15 |
BR112016020381A8 true BR112016020381A8 (pt) | 2018-05-02 |
Family
ID=52697553
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016020381A BR112016020381A8 (pt) | 2014-03-06 | 2015-03-06 | sistemas e métodos para liberação de drogas para tratamento do câncer de bexiga com gencitabina. |
Country Status (21)
Country | Link |
---|---|
US (3) | US20150250717A1 (pt) |
EP (2) | EP3113782B1 (pt) |
JP (4) | JP6901858B2 (pt) |
KR (1) | KR102338079B1 (pt) |
CN (1) | CN106102751A (pt) |
AU (3) | AU2015226901B2 (pt) |
BR (1) | BR112016020381A8 (pt) |
CA (1) | CA2939979C (pt) |
DK (1) | DK3113782T3 (pt) |
ES (1) | ES2930435T3 (pt) |
HR (1) | HRP20221252T1 (pt) |
HU (1) | HUE060704T2 (pt) |
IL (2) | IL311410A (pt) |
LT (1) | LT3113782T (pt) |
MX (1) | MX2016011333A (pt) |
PL (1) | PL3113782T3 (pt) |
PT (1) | PT3113782T (pt) |
RS (1) | RS63675B1 (pt) |
RU (1) | RU2694902C1 (pt) |
SG (2) | SG10202101978SA (pt) |
WO (1) | WO2015134911A1 (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2678308C2 (ru) | 2012-08-31 | 2019-01-25 | ТАРИС Биомедикал ЛЛК | Системы доставки лекарственного средства и способы лечения заболевания предстательной железы, включающие применение гемцитабина |
MX2016001621A (es) | 2013-08-19 | 2016-06-02 | Taris Biomedical Llc | Dispositivos y metodos de unidades multiples para administracion de farmacos. |
CA2939979C (en) * | 2014-03-06 | 2023-03-21 | Taris Biomedical Llc | Drug delivery systems and methods for treatment of bladder cancer with gemcitabine |
PL3452053T3 (pl) * | 2016-05-06 | 2023-05-08 | Taris Biomedical Llc | Sposób leczenia urotelialnego nowotworu złośliwego dolnych dróg |
CN110944645A (zh) * | 2017-07-25 | 2020-03-31 | 塔里斯生物医药公司 | 治疗肿瘤转移的方法 |
MX2020004771A (es) | 2017-11-08 | 2020-10-19 | Taris Biomedical Llc | Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina. |
US20220370630A1 (en) * | 2019-10-03 | 2022-11-24 | Seikagaku Corporation | Transmucosal delivery system for pharmaceutical active ingredient to submucosal tissue of bladder |
RU2713443C2 (ru) * | 2019-11-01 | 2020-02-05 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) | Способ комбинированного лечения мышечно-инвазивного рака мочевого пузыря т3-т4 n0-+m0 |
CN112169066B (zh) * | 2020-10-29 | 2023-05-12 | 安徽省立医院(中国科学技术大学附属第一医院) | 具有控制器的连续缓释给药留置管 |
CN113616666A (zh) * | 2021-08-24 | 2021-11-09 | 傅广波 | 膀胱黏膜下注射吉西他滨在治疗膀胱癌中的应用 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4111203A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system with means for improving delivery kinetics of system |
WO2004026281A2 (en) * | 2002-09-23 | 2004-04-01 | Microchips, Inc. | Micro-reservoir osmotic release systems and microtube array device |
US8361490B2 (en) * | 2004-09-16 | 2013-01-29 | Theracoat Ltd. | Biocompatible drug delivery apparatus and methods |
ES2400091T3 (es) | 2005-08-11 | 2013-04-05 | Massachusetts Institute Of Technology | Dispositivo de suministro de fármacos intravesical y método |
EP2049139A4 (en) * | 2006-04-24 | 2009-06-24 | Gloucester Pharmaceuticals Inc | TREATMENT OF TUMORS EXPRESSING RAS |
EA201070703A1 (ru) | 2007-12-11 | 2010-12-30 | Массачусетс Инститьют Оф Текнолоджи | Имплантируемое устройство для доставки лекарства и способы лечения мочевого пузыря и других полостей тела или трубчатых органов |
CA2733468C (en) | 2008-08-09 | 2017-12-05 | Massachusetts Institute Of Technology | Implantable drug delivery device and methods of treating male genitourinary and surrounding tissues |
US10543166B2 (en) | 2009-06-26 | 2020-01-28 | Taris Biomedical Llc | Implantable drug delivery devices and methods of making the same |
US9017312B2 (en) * | 2009-09-10 | 2015-04-28 | Taris Biomedical Llc | Implantable device for controlled drug delivery |
US8721621B2 (en) | 2009-09-10 | 2014-05-13 | Taris Biomedical, Inc. | Systems and methods for deploying devices to genitourinary sites |
JP2013514837A (ja) * | 2009-12-17 | 2013-05-02 | タリス バイオメディカル,インコーポレイテッド | 膀胱内における耐容性を備えた植込み型装置及び治療方法 |
DE212011100034U1 (de) * | 2010-01-20 | 2012-07-04 | Theracoat Ltd. | Material zur Behandlung von inneren Hohlräumen |
US20110218488A1 (en) | 2010-03-05 | 2011-09-08 | Taris Biomedical, Inc. | Systems and Methods for Implanting Devices in the Bladder and Other Genitourinary Sites |
WO2012048104A1 (en) | 2010-10-06 | 2012-04-12 | Taris Biomedical, Inc. | Implantable drug delivery device with bladden retention feature |
EP2624875A1 (en) | 2010-10-06 | 2013-08-14 | Taris Biomedical, Inc. | Time-selective bioresorbable or collapsible drug delivery systems and methods |
BR112013019410A2 (pt) * | 2011-02-04 | 2019-09-24 | Taris Biomedical Inc | dispositivo implantável para liberação controlada de fármaco de solubilidade baixa |
RU2678308C2 (ru) * | 2012-08-31 | 2019-01-25 | ТАРИС Биомедикал ЛЛК | Системы доставки лекарственного средства и способы лечения заболевания предстательной железы, включающие применение гемцитабина |
RU2669407C2 (ru) | 2013-03-15 | 2018-10-11 | ТАРИС Биомедикал ЛЛК | Устройства для доставки лекарственных средств и способы доставки лекарственных средств |
NZ711546A (en) * | 2013-03-15 | 2017-12-22 | Taris Biomedical Llc | Drug delivery devices with drug-permeable component and methods |
MX2016001621A (es) * | 2013-08-19 | 2016-06-02 | Taris Biomedical Llc | Dispositivos y metodos de unidades multiples para administracion de farmacos. |
CA2929554A1 (en) * | 2013-11-05 | 2015-05-14 | Taris Biomedical Llc | Osmotic drug delivery devices, kits, and methods |
CA2939979C (en) | 2014-03-06 | 2023-03-21 | Taris Biomedical Llc | Drug delivery systems and methods for treatment of bladder cancer with gemcitabine |
-
2015
- 2015-03-06 CA CA2939979A patent/CA2939979C/en active Active
- 2015-03-06 EP EP15711373.9A patent/EP3113782B1/en active Active
- 2015-03-06 ES ES15711373T patent/ES2930435T3/es active Active
- 2015-03-06 HR HRP20221252TT patent/HRP20221252T1/hr unknown
- 2015-03-06 US US14/641,009 patent/US20150250717A1/en not_active Abandoned
- 2015-03-06 RS RS20220937A patent/RS63675B1/sr unknown
- 2015-03-06 MX MX2016011333A patent/MX2016011333A/es unknown
- 2015-03-06 BR BR112016020381A patent/BR112016020381A8/pt not_active Application Discontinuation
- 2015-03-06 EP EP22196596.5A patent/EP4124339A1/en active Pending
- 2015-03-06 HU HUE15711373A patent/HUE060704T2/hu unknown
- 2015-03-06 IL IL311410A patent/IL311410A/en unknown
- 2015-03-06 LT LTEPPCT/US2015/019262T patent/LT3113782T/lt unknown
- 2015-03-06 SG SG10202101978SA patent/SG10202101978SA/en unknown
- 2015-03-06 JP JP2016555554A patent/JP6901858B2/ja active Active
- 2015-03-06 PT PT157113739T patent/PT3113782T/pt unknown
- 2015-03-06 RU RU2016136103A patent/RU2694902C1/ru active
- 2015-03-06 PL PL15711373.9T patent/PL3113782T3/pl unknown
- 2015-03-06 DK DK15711373.9T patent/DK3113782T3/da active
- 2015-03-06 WO PCT/US2015/019262 patent/WO2015134911A1/en active Application Filing
- 2015-03-06 CN CN201580011259.9A patent/CN106102751A/zh active Pending
- 2015-03-06 KR KR1020167027303A patent/KR102338079B1/ko active IP Right Grant
- 2015-03-06 SG SG11201607342QA patent/SG11201607342QA/en unknown
- 2015-03-06 AU AU2015226901A patent/AU2015226901B2/en active Active
-
2016
- 2016-08-18 IL IL247347A patent/IL247347A0/en unknown
-
2019
- 2019-10-04 JP JP2019184023A patent/JP7061595B2/ja active Active
-
2020
- 2020-08-12 AU AU2020217383A patent/AU2020217383B2/en active Active
-
2021
- 2021-11-11 JP JP2021183995A patent/JP7383681B2/ja active Active
- 2021-12-23 US US17/561,540 patent/US20220117886A1/en active Pending
-
2022
- 2022-07-07 US US17/811,296 patent/US20220347091A1/en active Pending
- 2022-08-08 AU AU2022215156A patent/AU2022215156A1/en active Pending
-
2023
- 2023-11-08 JP JP2023190543A patent/JP2024009034A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016020381A8 (pt) | sistemas e métodos para liberação de drogas para tratamento do câncer de bexiga com gencitabina. | |
CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
MX354210B (es) | Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas. | |
EA202091999A3 (ru) | Применение ингибиторов dpp iv | |
MY174727A (en) | Stable, protracted glp-1/glucagon receptor co-agonists for medical use | |
MX2014002668A (es) | Tratamiento de enfermedades relacionadas con subunidades alfa de canales de sonido regulados por voltaje (scnxa) con moleculas pequeñas. | |
BR112015005351A2 (pt) | sistemas para distribuição de drogas e métodos para tratamento de disfunção de esvaziamento da bexiga e outros distúrbios do trato urinário inferior | |
BR112015003836A2 (pt) | sistemas e métodos para distribuição de drogas para tratamento de câncer de bexiga | |
BR112014014181A2 (pt) | combinação de ozogamicina inotuzumab e torisel para o tratamento de câncer | |
BR112015004110A2 (pt) | sistemas e métodos de distribuição de drogas para tratamento de próstata | |
BR112015025424A2 (pt) | tratamento de câncer usando terapias de combinação de coenzima q10 | |
BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
AR088585A1 (es) | Un medicamento para tratar la enfermedad del ojo anterior | |
BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
TW201613578A (en) | Pharmaceutical combinations | |
BR112017006113A8 (pt) | usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits. | |
PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
BR112017006272A2 (pt) | composição farmacêutica para tratar colite ulcerativa. | |
UA118474C2 (uk) | (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині | |
UY33153A (es) | Formulación tópica oftálmica de péptidos | |
BR112017003552A2 (pt) | ?métodos para tratar caquexia, para tratar saciedade precoce, para aumentar o tempo de sobrevida, para melhorar a qualidade de vida e para aumentar a massa corporal total? | |
MX2022000394A (es) | Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer. | |
WO2014071168A3 (en) | Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122023008245-1 PROTOCOLO 870230035923 EM 28/04/2023 15:33. |
|
B12B | Appeal against refusal [chapter 12.2 patent gazette] |